We tested three of these NEU3 inhibitors in the mouse bleomycin model of pulmonary fibrosis, and all three (with one showing strong efficacy at 0.1 mg/kg) decreased fibrosis and TGF-β1 accumulation in the lung (supporting the model in Figure 1) when administered starting at day 10, with no discernable toxicity [84]. Here, NEU3 is linked to pulmonary fibrosis.